.png "Eli Lilly Strikes $1.12B Gene Editing Deal With Seamless")
Eli Lilly has entered a deal worth up to $1.12 billion with gene-editing firm Seamless Therapeutics, signaling a major push into advanced genetic treatments for hearing loss and rare diseases.
Lubrizol will participate in WHX Dubai 2026, spotlighting its expanding medical device manufacturing capabilities and new investments in India, including a high-precision medical tubing facility in Chennai set to open mid-2026.
India’s India-EU FTA opens access to a $572.3 billion pharma and MedTech market, cutting tariffs and boosting exports, jobs, and manufacturing across key Indian states.
Lupin Limited has earned the highest ‘A’ leadership rating from CDP for climate change and water security, reinforcing its position among global sustainability leaders in the pharmaceutical industry.
.jpeg "Health Ministry Mandates Blue Strip on All Antimicrobial Drugs")
Union Health Ministry drafts rules mandating blue strip on antimicrobial drugs to curb AMR. Public comments invited; aligns with PM Modi’s antibiotic safety emphasis.
Panchkula-based Venus Remedies has received its second PLI incentive payout for FY25, taking total disbursements to 75%. The release follows the company meeting investment, production, and sales targets under the scheme.
Zydus Lifesciences said its Ankleshwar manufacturing facility received three observations from the USFDA after a recent inspection, adding that none of the findings were linked to data integrity issues.
Naprod Life Sciences has secured an ANVISA GMP renewal for its Tarapur manufacturing facility, reinforcing its compliance with Brazil’s regulatory standards and supporting continued exports of oncology and specialty pharmaceutical products.
Akums Drugs secures EU GMP renewal for Plant 1 and first-time approval for Plant 2 in Haridwar, boosting its global CDMO presence in regulated pharma markets.
Sanofi’s amlitelimab, a promising treatment for moderate-to-severe atopic dermatitis (AD), has shown robust results in two global Phase 3 studies. The findings, along with a favorable safety profile, highlight its potential to improve patients’ quali
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")